The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
May. 29, 2018

Filed:

May. 06, 2016
Applicant:

Temple University of the Commonwealth System of Higher Education, Philadelphia, PA (US);

Inventors:

Kamel Khalili, Bala Cynwyd, PA (US);

Wenhui Hu, Cherry Hill, NJ (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 48/00 (2006.01); A61K 38/46 (2006.01); A61K 9/00 (2006.01); A61K 35/12 (2015.01); A61K 45/06 (2006.01); C12N 7/00 (2006.01); C12N 9/22 (2006.01); C12N 15/11 (2006.01); A61K 39/21 (2006.01); C12N 15/55 (2006.01); C12N 15/79 (2006.01); C12N 15/85 (2006.01); C12N 15/86 (2006.01);
U.S. Cl.
CPC ...
A61K 38/465 (2013.01); A61K 9/0034 (2013.01); A61K 35/12 (2013.01); A61K 45/06 (2013.01); A61K 48/00 (2013.01); A61K 48/005 (2013.01); C12N 7/00 (2013.01); C12N 9/22 (2013.01); C12N 15/111 (2013.01); C12N 2310/20 (2017.05); C12N 2320/30 (2013.01); C12N 2740/16063 (2013.01); C12Y 301/21 (2013.01);
Abstract

A method of inactivating a proviral DNA integrated into the genome of a host cell latently infected with a retrovirus by treating the host cell with a composition comprising a Clustered Regularly Interspaced Short Palindromic Repeat (CRISPR)-associated endonuclease, and two or more different guide RNAs (gRNAs), wherein each of the at least two gRNAs is complementary to a different target nucleic acid sequence in a long terminal repeat (LTR) in the proviral DNA, and inactivating the proviral DNA. A composition for use in inactivating a proviral DNA integrated into the genome of a host cell latently infected with a retrovirus including isolated nucleic acid sequences comprising a CRISPR-associated endonuclease and a guide RNA, wherein the guide RNA is complementary to a target sequence in a human immunodeficiency virus.


Find Patent Forward Citations

Loading…